Digna Biotech

Cardiotrophin I to Start Phase I Clinical Studies

Digna Biotech and CIMA Receive EUR 1.3 Million Funding for Acute Intermittent Porphyria Gene Therapy as Part of an EU FP7 Grant for Clinical Development of Orphan Drugs

MADRID and OEIRAS, Portugal, March 16, 2011 - Digna Biotech and Biotecnol (The Consortium) announced today that the Spanish Regulatory Medicine Agency has authorized the start of a Phase I Clinical Trial in healthy volunteers for Cardiotrophin-I (CT-I).

MORE..

Older News

MADRID, February 3, 2011 - Digna Biotech and the Centro de Investigacin Mdica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy